IMNN (Imunon Inc.) stock: $0.84, $4.7M market cap, $6.9M cash, -$2.2M EV, $9.0M fully diluted market cap. Lead program: IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) (Epithelial Ovarian Cancer), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
We operate in a highly competitive, highly regulated, and rapidly changing environment and our business is in a state of evolution. Therefore, it is likely that new risks will emerge, and that the nature and elements of existing risks will change.
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Share structure
Common
5.6M
Pre-funded warrants
1.0M
Options
0.3M
RSUs
0.0M
Warrants
3.9M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
10.7M
Cap table as of 2026-08-10.
Price history
Loading IMNN daily closes…
Loading price history…
Next catalyst
Paclitaxel · Aug 11 - Sep 22 in 9 mo · Phase 1/2 · Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Recently reported
IMNN-001 Phase 2Mixed · 2026-11-06
IMNN-001
Primary: Translational analysis of paired tumor biopsies from OVATION 2 (21 immune markers by cyclic immunofluorescence); OVATION 2 clinical benefit was measured by overall survival — IMNN-001 improved final median overall survival by 14.7 months (45.1 months versus 30.4 months) compared with the standard-of-care control arm in OVATION 2
· IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma in paired biopsies
· Median progression-free survival improved by three months in OVATION 2
· OVATION 2 enrolled 112 patients with newly diagnosed Stage III/IV epithelial ovarian cancer
· IMNN-001 dose in OVATION 2 was 100 mg/m2 administered intraperitoneally weekly, with neoadjuvant and adjuvant chemotherapy
· Pivotal Phase 3 OVATION 3 trial (NCT06915025) is currently enrolling
Epithelial Ovarian Cancer; Ovarian Cancer; Fallopian Tube Cancer
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 3 · ActiveModality: DNA plasmid immunotherapy (TheraPlas)
Target IL-12
Partnerships Break Through Cancer (Phase 2 minimal residual disease study collaboration)
Indications
Advanced ovarian cancer(Phase 3)
Status note Pivotal Phase 3 OVATION 3 trial in newly diagnosed advanced ovarian cancer ongoing; iDMC recommended continuation without modification in June 2026. FDA Fast Track designated. Phase 2 OVATION 2 completed.
IMNN-101
Phase 1 · ActiveModality: DNA vaccine (PlaCCine)
Target SARS-CoV-2 antigens
Indications
COVID-19 (seasonal booster)(Phase 1)
Status note Plasmid vector encoding multiple SARS-CoV-2 antigens. Phase 1 proof-of-concept study completed; company has paused further development and intends to seek partnership/business development opportunities.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Pipeline
Lead drug
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
—
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.